Please login to the form below

Not currently logged in
Email:
Password:

Sensipar

This page shows the latest Sensipar news and features for those working in and with pharma, biotech and healthcare.

Amgen buys Danish partner Nuevolution for $167m

Amgen buys Danish partner Nuevolution for $167m

The company is starting to face biosimilar competition for white blood cell stimulator Neulasta (pegfilgrastim) as well as generic encroachment on Sensipar (cinacalcet) for secondary hyperparathyroidism, which together accounted for around

Latest news

  • Amgen’s R&D chief Sean Harper retires to seek biotech post Amgen’s R&D chief Sean Harper retires to seek biotech post

    Bradway said two new products – Aimovig (erenumab) for migraine and Sensipar follow-up Parsabiv (etelcalcetide) for chronic kidney disease – had started well, and the quarter was also marked by the launch

  • NICE set to back Parsabiv for kidney disease complication NICE set to back Parsabiv for kidney disease complication

    be treated with Amgen's older drug Sensipar/Mimpara (cinacalcet) - and provided Amgen supplies the drug at an agreed discount. ... exceed Sensipar's sales at its peak, although rising levels of payer pushback in the US and elsewhere has led others to

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years. ... to be used in clinical practice, the monthly costs of Parsabiv and Sensipar should be comparable.".

  • Amgen wins European approval for Parsabiv Amgen wins European approval for Parsabiv

    Prior to that Parsabiv had been predicted to equal and potentially exceed Sensipar, which brought in more than $1.4bn last year, although it is starting to face  generic competition  in ... Amgen says Sensipar only has around 25% market penetration,

  • FDA knocks back Amgen's chronic kidney disease treatment FDA knocks back Amgen's chronic kidney disease treatment

    Amgen says Sensipar only has around 25% market penetration, mainly because of compliance issues associated with the need to dose the tablets orally every day. ... Sadly, Amgen failed to show that Sensipar could reduce the risk of death and cardiovascular

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics